Get started
HIMS & HERS HEALTH, INCHIMS & HERS HEALTH, INCHIMS & HERS HEALTH, INC

HIMS & HERS HEALTH, INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

HIMS trade ideas

HIMS puked up its Wegovy today!Hims & Hers Health HIMS shares were down more than 34.63% in Monday trading, while Novo Nordisk NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy. The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform. Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." This stock failed to catch a bid despite the equity markets strong.
NYSE:HIMS
by Trading-Capital
3
6/23/25 - $hims - Time to re-accumulate6/23/25 :: VROCKSTAR :: NYSE:HIMS Time to re-accumulate - NYSE:NVO are playing dirty and this is a tell and low-key admission that NYSE:HIMS holds all the power - distribution is key... look at NASDAQ:META , NASDAQ:AAPL , $AMZN. he who holds the customer relationship makes the rules - there is no longer a major advantage in developing pharma, the majority of solutions can now roll off patents and/or be compounded *legally* - so what you're seeing here is cartel-like behavior from a slow motion train wreck NYSE:NVO - which i've liked the past - but ultimately the stock will lose to names like NYSE:HIMS (and other pharma too). - so will they get sued? who tf cares. we'll buy more - this is a rule of 40 winner, even if law suit is large, it won't affect the story and growth. and major kudos to Andrew (the rockstar CEO) that put out this tweet. this is a founder-leader you want to put your portfolio behind when the opportunities arise. i'll be looking for oppty in the coming days/weeks to own more of this and would consider making it a decent size LT position at the right valuation, perhaps if we get back into the mid 30s. but i'm not holding my breath. this stock is scarce paper. and you know what happens to scarce paper in a USD ponzi scheme that is unwinding day by day by day. Andrew's post: x.com V
NYSE:HIMSLong
by VROCKSTAR
6
Safe Entry Zone HIMSAfter reaching the Target with 150% profit. Now the Blue Zone IC Zone(Interesting Zone or Institutional Candles Zone) is most appealing support level where we wait for Potentional of Strong Buyers to Step In. Note: Potentional of Strong Buying Zone: We have two scenarios must happen at The Mentioned Zone: Scenarios One: strong buying volume with reversal Candle. Scenarios Two: Fake Break-Out of The Buying Zone. Both indicate buyers stepping in strongly. NEVER Join in unless one showed up. Take Care.
NYSE:HIMS
by Faisalzor
HIMS – Sharp Sell-Off on Novo Nordisk Fallout. Overreaction?Today, Hims & Hers Health NYSE:HIMS plunged by –28%, breaking key support around $46. The sell-off was triggered by news that Novo Nordisk terminated its partnership with HIMS over the promotion of compounded alternatives to Wegovy, calling it “unethical.” 🔍 Key Drivers of the Drop: • Public fallout with Novo Nordisk • Very high trading volume (87M+) – panic selling • RSI and Stochastic both entered oversold zones • Key technical support at $46 was lost 🧠 Is this already priced in? Despite the controversy, HIMS remains a strong player in telehealth and personalized treatments. Their model isn’t solely dependent on this partnership. Investors may be overreacting. 📌 Idea: Rebound from panic-driven drop • Entry zone: $45–46 • Target 1: $55 • Target 2: $65 (retest previous highs) • Stop loss: $40 💬 Watch for official statements from HIMS and updates on new partnerships.
NYSE:HIMSShort
by ALVO13_official
 $HIMS | Direction: Long | Key Reason: Macro | (June 19, 2025)  NYSE:HIMS | Direction: Long | Key Reason: Macro & Technical | (June 19, 2025) 1️⃣ Insight Summary We’re watching for a healthy pullback into the $31–$30.10 zone on NYSE:HIMS before entering. That drop should align with both fundamental value and technical support, setting the stage for a strong bounce. 2️⃣ Trade Parameters Bias: Long Entry: Around $31.00–$30.10 Stop Loss: Below $21.00, with a hard stop at $19.00 if price breaks structure Take Profit 1: $44.00 Take Profit 2: $59.71 3️⃣ Key Notes ✅ Fundamentals are solid: Revenue ~1.48B, net income ~200M, market cap ~113B. 2024 marked the first profitable year. Debt sits @ $11M, while free cash flow is ~$1.098B—low debt relative to cash flow. ✅ Ratings & margins: ~14% free cash margin, realistic forward estimates, stable beta (~3.2) and 0.15 EPS. ✅ Risk/Reward profile: Entry gives ~10–11 points of downside vs. ~13–29 points upside to targets. ✅ Technical scenario: A pullback to $30–31 acting as support would confirm our bias—monitor price action closely in this zone. ✅ Sector tailwinds: Continued momentum in telehealth, mental health, and AI-driven medical services supports upside potential. 4️⃣ Follow‑up Note If NYSE:HIMS drops into our entry zone and shows a solid bounce or structure retest, we’ll confirm the long setup. From there, our targets at $44 and $59.71 come into clearer focus. Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. Disclaimer: This is not financial advice. Always conduct your own research. This content may include enhancements made using AI.
NYSE:HIMS
by Risk_Adj_Return
Where is HIMS set to go next?Overview of Hims & Hers Health (NYSE: HIMS): Pros Expanding into weight-loss treatments -Hims successfully entered the high-demand GLP‑1 weight-loss space by selling compounded semaglutide during shortages. With branded Wegovy now available on their platform in partnership with Novo Nordisk, they’ve broadened their offering. Solid growth & rising profitability -Revenue surged ~18% in 2024 to $1.78 b ttm, with annual net income of $164 m. -Q1 2025 reported >100% YoY revenue growth ($586 m) with expected profit of 20¢/share. Strong gross margins -At around 80–88%, comparable to peer telehealth platforms. Diverse healthcare offerings -Beyond weight loss: sexual health, skincare, hair loss, mental health via DTC model. Expanded further via European acquisition of ZAVA (~1.3 m subscribers). Undervalued relative to future earnings -Analysts project 2030 revenues of $6.5 b—implying mid‑20s% CAGR. With projected EPS ~$1.5 b, current multiples (P/E ~40x) might look reasonable long term. Cons GLP‑1 strategy under pressure -The end of compounding allowances by FDA reduced their low-cost advantage. -Dependence on cash-pay vs. insurer coverage may limit growth if insurers cap co-pays. High valuation with risk -Trading at ~84x trailing EPS and ~70x forward EPS—wide margin for missteps. -Analysts average target at $38 (≈ 33% downside), 12 rate it a 'Hold'. Competitive & regulatory headwinds -Market crowded with telehealth players like Ro, Noom, CVS, and insurers which may undercut cash-pay model. -Legal scrutiny over “personalized” compounded products persists; Novo lawsuits underway. Reputation & controversy -CEO’s political donation stirred backlash; regulatory scrutiny around ads and compounding practices. -Platform has faced occasional service and customer trust issues. -Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Stock prices, valuations, and performance metrics are subject to change and may be outdated. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. The information presented may contain inaccuracies and should not be solely relied upon for financial decisions. I am not personally liable for your own losses, this is not financial advise.
NYSE:HIMS
by bossout10
1
$HIMS setting up for its next big move—here’s what I’m watching!🔥 NYSE:HIMS setting up for its next big move—here’s what I’m watching! 🔥 📉 Eyeing momentum down to $44-$48, and I’m not mad about it! 🔄 That flip from resistance to support is key for long-term price growth. 🚀 Bull flag breakout could come sooner—stay locked in! Keeping an eye on it all for the next trade entry on this beast! 💬 What’s your take? Are we bouncing or breaking out? Drop your thoughts below! ⬇️
NYSE:HIMSLong
by RonnieV29
2
HIMS – Technically and Fundamentally Strong for Mid-to-Long TermTechnical Analysis HIMS is trading in a clear ascending channel since 2023. On the daily chart, a “cup and handle” formation has completed, with a confirmed breakout above the neckline ($55–$57 area). The price is consolidating near the breakout point – classic behavior before a continuation move. Target projection from the cup pattern is $170+, implying a 200%+ upside potential. The stock also respects the upper trendline of the long-term channel, reinforcing bullish structure. Fundamental Strength: Telemedicine megatrend: Digital health is booming. HIMS is one of the few well-established D2C players in the U.S. market. Revenue growth: Annual revenue growth exceeds 40% YoY, a sign of operational efficiency and demand. Sticky subscription model: Over 1.5 million active subscribers — solid base for recurring revenue and LTV. Valuation upside: Still undervalued relative to sector peers despite recent rally. Scalable tech stack: Strong backend, customer acquisition systems, and vertically integrated infrastructure support further expansion. Conclusion: HIMS offers an attractive risk–reward setup for swing traders and long-term investors alike
NYSE:HIMSLong
by InvestWorld_777
HIMS Weekly Options Outlook — June 3, 2025📉 HIMS Weekly Options Outlook — June 3, 2025 🚨 AI Model Consensus: Moderately Bearish into June 6 Expiry 🧠 Model Overview 🔹 Grok (xAI) Bias: Neutral Setup: Bearish short-term, bullish long-term; mixed outlook Trade: No action — lacks edge Confidence: 35% 🔹 Claude (Anthropic) Bias: Moderately Bearish Setup: Below EMAs, bearish MACD; cautious sentiment Trade: Buy $52P @ $0.94 → PT $1.88+, SL $0.56 Confidence: 72% 🔹 Llama (Meta) Bias: Moderately Bearish Setup: Post-run fractal pullback, mixed but leaning down Trade: Buy $52P → PT +20%, SL −50% Confidence: 70% 🔹 Gemini (Google) Bias: Moderately Bearish Setup: Clean break under EMAs, MACD/RSI confirm weakness Trade: Buy $50P @ ~$0.47 → PT 100%, SL 50% Confidence: 65% 🔹 DeepSeek Bias: Moderately Bearish Setup: Breakdown across timeframes; skewed put flow Trade: Buy $50P @ $0.45 → PT $0.70, SL $0.32 Confidence: 65% ✅ Consensus Summary 📉 4 of 5 models recommend bearish weekly puts 🔻 Clear breakdown under EMAs with supportive MACD/RSI signals 🧲 Max Pain at $55 could cause late-week pullback or stall 🎯 Preferred strategy: OTM naked puts with high ROI potential 🎯 Recommended Trade Setup 💡 Strategy: Weekly Bearish Put Play 🔘 Ticker: HIMS 📉 Direction: PUT 🎯 Strike: $52 💵 Entry: $0.94 (ask) 🎯 Profit Target: $1.70 (+80%) 🛑 Stop Loss: $0.56 (−40%) 📏 Size: 1 contract 📅 Expiry: 2025-06-06 ⏰ Entry Timing: Market Open 📈 Confidence: 70% ⚠️ Risk Factors to Watch 🧲 Max pain at $55 could slow breakdown or cause snapback 🔻 $52 support zone may cause consolidation or chop 📉 Falling VIX = compressed premiums, slower option movement ⌛ Theta accelerates into Thursday/Friday — exit early if flat
NYSE:HIMSShort
by quantsignals
Hims is OVERBOUGHT Market Context ✨ NYSE:HIMS | Current Price: $42.00 1-Month Move: +17.5% (from $35.75) 1-Year Move: +68.2% (from $25.00) Year High/Low: $43.50/$24.80 Technicals RSI: ~75.8 (overbought ) Moving Averages: Above 20-day, 50-day, and 200-day MAs (strong uptrend, but overextended ) MACD: Bearish divergence forming (momentum fading, potential reversal ) Trade Setup Direction: PUT Entry Price: $42.00 Take Profit 1 (TP1): $36.00 (~14.3% gain ) Take Profit 2 (TP2): $30.00 (~28.6% gain ) Expected Move: ~12–15% downward Best AI Signals on the market
NYSE:HIMSShort
by AlphaSignals_ai
5
Hims set to correctHims is pulling yet another amazing short squeeze. The stock has become my largest position by far since I got in back around 7$. These supply and demand zones have been drawn for a while. Note the amazing consolidation and push from the green demand box. 73$ would be double top mode. While I love the fundamentals I am not sure if the stock sis worth 70$ until we see next earnings which shouldn't be amazing because of their stated margin decreases, the market will panic like it always does. I would LOVE a retest of 35$, but 45$ is more likely.
NYSE:HIMSShort
by Apollo_21mil
HIMS – Pullback Opportunity After Massive RunHIMS has been one of the hottest stocks in the market recently, with a massive run fueled by strong earnings. But now we’re seeing the first meaningful pullback — and this could be a golden opportunity: 🔹 Earnings Gap Reversal (Bullish Signal) Despite an earnings gap down, buyers stepped in aggressively, pushing the stock higher. This is a classic earnings gap down reversal — a strong sign of demand. 🔹 First Pullback Opportunity Historically, the first pullback after a major run tends to get bought. I’m watching two key levels for a potential buy: The shaded zone between the 9 EMA and 20 EMA (dynamic support). The 0.38 - 0.50 Fibonacci retracement for added confirmation. 🔹 My Trading Plan: 1️⃣ Initial Entry: Starter position in the shaded EMA zone (9 EMA - 20 EMA). 2️⃣ Confirmation Add: If price bounces off the Fib zone (0.38 - 0.50) with strength. 3️⃣ Stop Loss: Below the 20 EMA for any initial position — keeping risk tight. 🔹 Why This Setup is Compelling: Strong run + earnings reversal shows real buyer interest. First pullback after a big run is typically a strong buying opportunity. The dual confluence of EMAs + Fibonacci enhances this setup. ⚠️ Risk Management: Tight stop below 20 EMA — always control risk.
NYSE:HIMSLong
by kunal00
1